About Medcura
Medcura is a private company based in Riverdale, Maryland. It has reported $60,180,808 raised in seven offerings on Form D since April 2016.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 16, 2025 | Jul 25, 2025 | $28,548,588of $38.2M target | 174 | $164K | Equity, Convertible Promissory Notes; Series B Preferred Stock underlying the convertible promissory notesRule 506(b) | Form D ↗ |
| Jul 29, 2022 | Aug 16, 2022amended Jul 24, 2024 | $22,486,953of $22.8M target | 151 | $148K | Equity, Debt, Options, Securities on exercise, Convertible Promissory Notes; Common Stock or Series A-1 Preferred Stock underlying the convertible promissory notes.Rule 506(b) | Form D/A ↗1 earlier filing |
| Oct 15, 2021 | Nov 2, 2021 | $3,490,000of $5.7M target | 45 | $77,556 | Equity, Debt, Options, Securities on exercise, Convertible Promissory Notes, including Common Stock or Preferred Stock into which the notes can be converted.Rule 506(b) | Form D ↗ |
| Jun 19, 2020 | Sep 28, 2020 | $3,021,475of $5.0M target | 55 | $54,936 | Debt, OptionsRule 506(b) | Form D ↗ |
| Jun 18, 2018 | Jul 2, 2018 | $1,561,500of $2.5M target | 36 | $43,375 | Debt, OptionsRule 506(b) | Form D ↗ |
| Sep 9, 2016 | Sep 20, 2016amended Nov 10, 2016 | $1,072,281of $3.1M target | 14 | $76,592 | Equity, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 29, 2016 | Apr 14, 2016 | $11of $200 target | 1 | $11 | EquityRule 506(b) | Form D ↗ |
| Total, seven offerings | $60,180,808 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Medcura's Form D filed Jul 25, 2025.
RV
Rich Vincent
Executive officer
JB
Jim Buck
Executive officer and director
LT
Larry Tiffany
Executive officer and director
AD
Abbas Ardehali, M.D.
Director
MD
Matthew Dowling, Ph.D
Executive officer and director
Earlier filings also listed Matthew Dowling (chief scientific officer and director, last listed Nov 2021), Alexander Arrow (director, last listed Sep 2020) and Peter Thomas (executive officer and director, last listed Apr 2016).